Interactions between Myc and Mediators of Inflammation in Chronic Liver Diseases

被引:60
作者
Liu, Ting [1 ]
Zhou, Yu [2 ]
Ko, Kwang Suk [3 ]
Yang, Heping [4 ]
机构
[1] Cent S Univ, Xiangya Hosp, Dept Gastroenterol, Changsha 410008, Hunan, Peoples R China
[2] Univ So Calif, Keck Sch Med, GI Liver Ctr, Los Angeles, CA 90033 USA
[3] Ewha Womans Univ, Coll Hlth Sci, Dept Nutr Sci & Food Management, Seoul 150750, South Korea
[4] Cedars Sinai Med Ctr, Dept Med, Div Gastroenterol, Los Angeles, CA 90048 USA
基金
中国国家自然科学基金;
关键词
NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; HEPATIC STELLATE CELLS; C-MYC; FATTY LIVER; SOLUBLE INTERLEUKIN-2-RECEPTOR; TRANSCRIPTION FACTORS; RECEPTOR ANTAGONIST; BILIARY-CIRRHOSIS; IL-8; EXPRESSION;
D O I
10.1155/2015/276850
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Most chronic liver diseases (CLDs) are characterized by inflammatory processes with aberrant expressions of various pro-and anti-inflammatory mediators in the liver. These mediators are the driving force of many inflammatory liver disorders, which often result in fibrosis, cirrhosis, and liver tumorigenesis. c-Myc is involved in many cellular events such as cell growth, proliferation, and differentiation. c-Myc upregulates IL-8, IL-10, TNF-alpha, and TGF-beta, while IL-1, IL-2, IL-4, TNF-alpha, and TGF-beta promote c-Myc expression. Their interactions play a central role in fibrosis, cirrhosis, and liver cancer. Molecular interference of their interactions offers possible therapeutic potential for CLDs. In this review, current knowledge of the molecular interactions between c-Myc and various well known inflammatory mediators is discussed.
引用
收藏
页数:12
相关论文
共 139 条
  • [61] Mature T lymphocyte apoptosis - Immune regulation in a dynamic and unpredictable antigenic environment
    Lenardo, M
    Chan, FKM
    Hornung, F
    McFarland, H
    Siegel, R
    Wang, J
    Zheng, LX
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 : 221 - 253
  • [62] Link J. M., 2014, BIOCH BIOPHYSICA ACT
  • [63] ACTIVATION OF RAS ONCOGENE IN LIVERS WITH CIRRHOSIS
    LIU, P
    FLEJOU, JF
    FELDMANN, G
    BERNUAU, D
    [J]. JOURNAL OF HEPATOLOGY, 1994, 21 (06): : 1103 - 1108
  • [64] Activation of NF-kappaB, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas
    Liu, P
    Kimmoun, E
    Legrand, A
    Sauvanet, A
    Degott, C
    Lardeux, B
    Bernuau, D
    [J]. JOURNAL OF HEPATOLOGY, 2002, 37 (01) : 63 - 71
  • [65] AP-1 blockade in breast cancer cells causes cell cycle arrest by suppressing G1 cyclin expression and reducing cyclin-dependent kinase activity
    Liu, YM
    Lu, CH
    Shen, Q
    Munoz-Medellin, D
    Kim, H
    Brown, PH
    [J]. ONCOGENE, 2004, 23 (50) : 8238 - 8246
  • [66] Loboda A, 2009, ANTIOXID REDOX SIGN, V11, P1501, DOI 10.1089/ARS.2008.2211
  • [67] Regulation of inflammation by interleukin-4: a review of "alternatives"
    Luzina, Irina G.
    Keegan, Achsah D.
    Heller, Nicola M.
    Rook, Graham A. W.
    Shea-Donohue, Terez
    Atamas, Sergei P.
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2012, 92 (04) : 753 - 764
  • [68] Bacterial Infection of Smad3/Rag2 Double-Null Mice with Transforming Growth Factor-β Dysregulation as a Model for Studying Inflammation-Associated Colon Cancer
    Maggio-Price, Lillian
    Treuting, Piper
    Bielefeldt-Ohmann, Helle
    Seamons, Audrey
    Drivdahl, Rolf
    Zeng, Weiping
    Lai, LapHin
    Huycke, Mark
    Phelps, Susan
    Brabb, Thea
    Iritani, Brian M.
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (01) : 317 - 329
  • [69] Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes
    Matsusue, K
    Haluzik, M
    Lambert, G
    Yim, SH
    Gavrilova, O
    Ward, JM
    Brewer, B
    Reitman, ML
    Gonzalez, FJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (05) : 737 - 747
  • [70] The Inflammasome in Liver Injury and Non-Alcoholic Fatty Liver Disease
    Mehal, Wajahat Zafar
    [J]. DIGESTIVE DISEASES, 2014, 32 (05) : 507 - 515